AbbVie Opens 250 Entrepreneur Grants While Forecasting 45.4% Earnings Growth
AbbVie’s Botox Cosmetic program opens applications for 250 women entrepreneurs, awarding twenty $20k grants, boosting brand engagement through April 29. The company also reported over a decade of consecutive dividend increases, a 3.2% yield, and forecasts 45.4% earnings growth in 2026 driven by Skyrizi and Rinvoq reaching $50 billion by 2030.
1. Launch of Confidence Collective
AbbVie’s Botox Cosmetic brand has opened applications through April 29 for The Confidence Collective, selecting 250 women entrepreneurs for resources, coaching and community support. Twenty finalists will each receive $20,000 grants to accelerate business growth and close the confidence gap among women founders.
2. Consecutive Dividend Increases
Since its 2013 spin-off, AbbVie has raised its dividend every year for over a decade and currently offers a 3.2% yield. This consistent payout policy underscores the company’s commitment to returning capital to shareholders despite Humira patent expirations.
3. Growth Drivers and Earnings Outlook
AbbVie attributes its strong earnings forecast—a projected 45.4% increase in 2026—to rapid adoption of immunology drugs Skyrizi and Rinvoq. These products are expected to generate combined revenues of $50 billion by 2030, offsetting Humira’s revenue declines.